Publication
Article
BioPharm International
BioPharm International-03-01-2003Volume16 Issue 3
Inside Washington: The Big Shift
Author(s):
Jill Wechsler FDA explains its plan for moving most biologics under the authority of CDER. But a big question remains: What will the change do to approval times?
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Videos
Related Content
